[go: up one dir, main page]

MX2019001337A - Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer. - Google Patents

Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.

Info

Publication number
MX2019001337A
MX2019001337A MX2019001337A MX2019001337A MX2019001337A MX 2019001337 A MX2019001337 A MX 2019001337A MX 2019001337 A MX2019001337 A MX 2019001337A MX 2019001337 A MX2019001337 A MX 2019001337A MX 2019001337 A MX2019001337 A MX 2019001337A
Authority
MX
Mexico
Prior art keywords
side effects
cancer treatment
treating
methods
preventing cancer
Prior art date
Application number
MX2019001337A
Other languages
English (en)
Inventor
P Cirrito Thomas
M Rochlin Kate
Original Assignee
Filament Biosolutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Filament Biosolutions Inc filed Critical Filament Biosolutions Inc
Publication of MX2019001337A publication Critical patent/MX2019001337A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan formulaciones de Alanil-glutamina (Ala-Gln) para utilizarse en tratar y prevenir los efectos secundarios asociados con el tratamiento del cáncer. También se proporcionan en la presente los métodos para utilizar las formulaciones proporcionadas en la misma para tratar o prevenir los efectos secundarios asociados con el tratamiento del cáncer.
MX2019001337A 2016-08-01 2017-07-31 Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer. MX2019001337A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662369424P 2016-08-01 2016-08-01
PCT/US2017/044655 WO2018026703A1 (en) 2016-08-01 2017-07-31 Methods of treating and preventing cancer treatment side effects

Publications (1)

Publication Number Publication Date
MX2019001337A true MX2019001337A (es) 2019-09-23

Family

ID=61073276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001337A MX2019001337A (es) 2016-08-01 2017-07-31 Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.

Country Status (7)

Country Link
US (2) US20190175685A1 (es)
EP (1) EP3490971A4 (es)
JP (3) JP2019527707A (es)
AU (1) AU2017306050A1 (es)
CA (1) CA3032398A1 (es)
MX (1) MX2019001337A (es)
WO (1) WO2018026703A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111072755B (zh) * 2020-01-06 2023-09-05 湖北泓肽生物科技有限公司 力肽络合物、其药物组合物、其制备方法和应用
US20220211752A1 (en) * 2020-11-25 2022-07-07 The Trustees Of Columbia University In The City Of New York Methionine and cysteine deprivation diet and formulations to increase effectiveness of cancer therapy
US20230346741A1 (en) * 2022-03-04 2023-11-02 Cas Properties, Llc Eriodictyol compositions and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03148216A (ja) * 1989-11-02 1991-06-25 Morishita Pharmaceut Co Ltd 高濃度ｌ―グルタミンペプチド水溶液
WO2000068251A1 (en) * 1999-05-07 2000-11-16 The University Of Virginia Patent Foundation Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
CN101084003A (zh) * 2004-12-21 2007-12-05 重症救护联络公司 治疗性营养组合物或联合药物及其使用方法
WO2006102337A2 (en) * 2005-03-22 2006-09-28 Destura, Raul L-arginine and zinc supplementation for repair of intestinal epithelial cell injury
JPWO2007119503A1 (ja) * 2006-03-23 2009-08-27 協和発酵バイオ株式会社 寝起き改善剤
US9119416B2 (en) * 2006-03-23 2015-09-01 Kyowa Hakko Bio Co., Ltd. Muscle fatigue remedy
US10426813B2 (en) * 2009-11-06 2019-10-01 Kyowa Hakko Bio Co., Ltd. Method to enhance endurance
JP2012041324A (ja) * 2010-08-23 2012-03-01 Ajinomoto Co Inc 白金含有薬剤投与による肝機能低下の抑制剤
GB201108343D0 (en) * 2011-05-18 2011-06-29 Hibernation Honey Ltd Honey composition
US20130225684A1 (en) * 2012-02-28 2013-08-29 Kyowa Hakko Bio Co., Ltd. Methods and compositions for enhancement of vision performance
ES2733123T3 (es) * 2014-05-23 2019-11-27 Kyowa Hakko Bio Co Ltd Métodos y composiciones para la potenciación de la capacidad de concentración

Also Published As

Publication number Publication date
EP3490971A4 (en) 2020-02-26
US20240261363A1 (en) 2024-08-08
US20190175685A1 (en) 2019-06-13
JP2022153573A (ja) 2022-10-12
WO2018026703A1 (en) 2018-02-08
JP2019527707A (ja) 2019-10-03
JP2024150744A (ja) 2024-10-23
CA3032398A1 (en) 2018-02-08
EP3490971A1 (en) 2019-06-05
AU2017306050A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
ZA201903327B (en) Compositions and methods for the induction of cd8+ t¿cells
WO2017096309A8 (en) Methods of treatment of malignancies
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
ZA201802966B (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MY208231A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
PH12017550063A1 (en) Combination therapies for treating cancers
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2017003797A (es) Macrociclos peptidomimeticos y usos de los mismos.
MX2024014239A (es) Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
GEP20217317B (en) Combination therapy for the treatment of cancer
WO2016043874A3 (en) Combination therapy for treating cancer
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
IL275517A (en) Combined methods and treatment of cancer
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
EP4549467A3 (en) Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
MX2019013862A (es) Terapia de combinacion.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.